Physician profile
Desiree D Brotsky
NPI 1043422777
$3,625.03
in general payments reported to CMS, 2019-2025
28 companies · $571 in 2025
The $571 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $234 · 2021: $667 · 2022: $887 · 2023: $603 · 2024: $517 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.49 | 2020-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Mayne Pharma Commercial LLC | $543.38 | 2022-2025 | |
| Daiichi Sankyo INC. | $248.19 | 2021-2022 | |
| Astellas Pharma US INC | $197.48 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $168.41 | 2021-2022 | |
| Hologic Sales and Service, LLC | $143.58 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Bayer Healthcare Pharmaceuticals INC. | $132.32 | 2019-2025 | |
| Pfizer INC. | $124.26 | 2019-2025 | |
| Coopersurgical, INC. | $121.39 | 2020-2025 | Paragard T 380a, Endosee |
| Evofem Biosciences, INC. | $116.58 | 2021-2023 | Phexxi |
| Sumitomo Pharma America, INC. | $104.51 | 2023-2025 | Myfembree |
| Minerva Surgical, INC | $86.70 | 2019-2023 | |
| Organon LLC | $82.90 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $80.64 | 2019-2021 | |
| Avion Pharmaceuticals | $79.97 | 2020-2023 | Balcoltra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $78.56 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $65.80 | 2022-2025 | Slynd |
| Agile Therapeutics, INC. | $59.28 | 2021-2023 | Twirla |
| Mylan Pharmaceuticals INC. | $50.45 | 2021-2022 | |
| Aspira Women'S Health INC | $47.02 | 2024 | Ova1 |
| Baxter Healthcare | $44.99 | 2021 | |
| Millicent US INC | $36.05 | 2024-2025 | Femring, Intrarosa |
| Allergan, INC. | $32.29 | 2019 | |
| Duchesnay USA Incorporated | $30.38 | 2019 | |
| Edwards Lifesciences Corporation | $18.94 | 2024 | |
| Optumhealth Care Solutions, LLC | $15.67 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Shield Therapeutics INC | $12.97 | 2022 | |
| Scynexis, INC. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Brotsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.